Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

Delayed Quote. Delayed  - 09/23 05:35:17 pm
36.93 EUR   -0.81%
09/23 MORPHOSYS : to Present at Upcoming Investor Conferences
09/19 MORPHOSYS : Lanthio Pharma Expands Management Team
09/12 MORPHOSYS : Appoints Four R&D Experts to its Newly Formed Scientific..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
09/19/2016 09/20/2016 09/21/2016 09/22/2016 09/23/2016 Date
36.205(c) 36(c) 35.9(c) 37.23(c) 36.93(c) Last
100 153 93 231 60 338 160 968 93 263 Volume
+0.17% -0.57% -0.28% +3.70% -0.81% Change
More quotes
Financials (€)
Sales 2016 49,2 M
EBIT 2016 -64,6 M
Net income 2016 -50,7 M
Finance 2016 213 M
Yield 2016 -
Sales 2017 60,9 M
EBIT 2017 -33,3 M
Net income 2017 -48,7 M
Finance 2017 84,8 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 15,6x
EV / Sales2017 14,7x
Capitalization 980 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
09/23 MORPHOSYS : to Present at Upcoming Investor Conferences
09/19 MORPHOSYS : Lanthio Pharma Expands Management Team
09/12 MORPHOSYS : Appoints Four R&D Experts to its Newly Formed Scientific Advisory Bo..
09/06 MORPHOSYS : Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine ..
08/29 MORPHOSYS : to Present at Upcoming Investor Conferences
08/18 MORPHOSYS : "Anti-CD38 Antibody and Lenalidomide Or Bortezomib for the Treatment..
08/17 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
08/17 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
08/17 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
08/17 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
More news
Sector news : Biotechnology & Medical Research - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/21 MorphoSys (MPSYY) Presents at Bank of America Merrill Lynch 2016 Global Healt..
08/01 MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2016 Results - Earnings Call Trans..
08/01 MorphoSys AG 2016 Q2 - Results - Earnings Call Slides
08/01 MorphoSys AG reports H1'16 results
05/03 MorphoSys' (MPSYF) CEO Simon Moroney on Q1 2016 Results - Earnings Call Trans..
Advertisement
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 58,3 €
Spread / Average Target 58%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-35.94%1 100
INCYTE CORPORATION-17.95%16 728
CELLTRION, INC.--.--%11 664
LONZA GROUP AG13.18%10 059
QUINTILES TRANSNATIONA..15.66%9 453
SEATTLE GENETICS, INC.24.40%7 845
More Results